NYU Langone Identifies Key Protein Driving Melanoma Growth, Immune Evasion
Event summary
- NYU Langone researchers have identified HOXD13, a transcription factor, as a key driver of melanoma growth and immune evasion.
- HOXD13 promotes angiogenesis by stimulating pathways involving VEGF, SEMA3A, and CD73, and suppresses cytotoxic T cell activity.
- Suppression of HOXD13 led to tumor shrinkage and increased T cell infiltration in experiments.
- Clinical trials are already underway testing VEGF and adenosine-receptor inhibitors, with plans to combine them for HOXD13-driven melanoma.
- The research analyzed tumor samples from over 200 melanoma patients across three countries (U.S., Brazil, Mexico).
The big picture
The identification of HOXD13 as a central regulator in melanoma progression represents a significant advancement in cancer research, potentially opening new avenues for targeted therapies. This discovery aligns with the broader trend of leveraging genomic insights to develop personalized cancer treatments, particularly those that combine immunotherapy with targeted drug approaches. The potential application of this approach to other cancers, such as glioblastomas and sarcomas, could significantly expand the market opportunity for these therapies.
What we're watching
- Clinical Progress
- The success of ongoing clinical trials evaluating VEGF and adenosine-receptor inhibitors will be crucial in determining the viability of a combined treatment approach for HOXD13-driven melanoma.
- Expansion Potential
- How effectively Hernando-Monge’s team can expand the targeting of VEGF and adenosine pathways to other cancers with elevated HOXD13 will influence the therapeutic impact of this discovery.
- Mechanism Validation
- Whether the observed correlation between HOXD13 levels and T cell suppression in melanoma patients holds true in larger, more diverse patient cohorts needs to be validated.
Related topics